Press release BoxID: 424652 (Vetter Pharma International GmbH)
  • Vetter Pharma International GmbH
  • Eywiesenstraße 5
  • 88212 Ravensburg
  • Contact person
  • Oskar Gold
  • +49 (751) 3700-0

Structural Work Completed on New Ravensburg-Area Vetter Facility

State-of-the-art center for visual inspection and logistics on schedule for launch

(PresseBox) (Ravensburg, ) Structural work on Vetter's new German facility Ravensburg Vetter West has been completed within eleven months of groundbreaking. As scheduled, the company concluded structural work on its center for visual inspection and state-of-the-art high-bay warehouse for cold-storage and room-temperature products. Interior work and the construction of an environmentally friendly power supply system will be finished by late 2011, when operations will begin. In addition to photovoltaics and biogas, the facility will also use geothermal sources of power. More than 20 companies from the region participated in the implementation of the 31-million-Euro project. The facility will employ more than 230 staff.

With its new center for visual inspection and logistics, located in the industrial area of Erlen, adjacent to Ravensburg, Vetter further meets the needs of its international customers. The facility offers optimized quality control processes and material supply, enabling even more efficient and reliable product delivery around the world. To respond to the growing demand for stability tests, the center will offer advanced-design stability chambers, with expanded capacity for long-term stability testing under a range of temperatures.

The facility will harness renewable energy across the site: Vetter is installing photovoltaic cells on the facade to generate solar electricity. The company is also collaborating with regional farmers who run, exclusively for Vetter, a biogas plant used to operate a block heating and power plant within the company's site. Geothermal energy will be used to regulate temperatures in the high-bay warehouse.

"Our new facility in Erlen reinforces Vetter's position in international markets," says Thomas Otto, Vetter Managing Director. "It combines efficiency and sustainability, and its advanced processes support a high level of product and delivery security. Our investment both in the facility and in renewable energy testifies to our commitment to the region. In Erlen, we are laying important groundwork for Vetter's continuing growth and success on the world market."

Vetter Pharma International GmbH

Vetter is an independent international specialist in the aseptic filling of syringes, cartridges and vials. The company has extensive experience with a broad array of substances, including monoclonal antibodies, peptides, interferons and vaccines. Headquartered in Ravensburg, Germany, Vetter provides support for pharmaceutical and biotech clients from preclinical development through regulatory approval and global market supply. Vetter’s new Chicago facility, an expansion of Vetter Development Service, supports early-stage products. The firm works with the world’s leading pharmaceutical and biotech companies and employs approximately 2,400 staff across Europe and the United States . The innovator of the Vetter Lyo-Ject® dual-chamber syringe and V-LK® cartridge, the company holds nearly 140 patents and is a leader in the use of RABS technology in cleanrooms. Approved as a foreign manufacturer by the government of Japan, Vetter’s global regulatory experience includes numerous customer product approvals by the FDA, EMA and other authorities. Over its more than 25-year history in aseptic filling, Vetter has won many awards for its facilities and operations, including the 2010 SAP EMEA Quality Award, silver medal, for the implementation of a companywide planning software system.